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Abstract
Aging is a complex and highly variable process. Heritability of longevity among humans and other 
species is low, and this has given rise to the idea that it may be futile to search for gene variants 
that control rates of aging. We argue that the problem is mainly due to low power and the genetic 
and environmental complexity of longevity. In this review we highlight progress made in mapping 
genes and molecular networks associated with longevity, paying special attention to work in mice 
and humans. We summarize 40 years of linkage studies using murine cohorts and 15 years of 
studies in human populations that have exploited candidate gene and genome-wide association 
methods. A small but growing number of gene variants contribute to known longevity 
mechanisms, but a much larger set have unknown functions. We outline these and other challenges 
and suggest some possible solutions, including more intense collaboration between research 
communities that use model organisms and human cohorts. Once hundreds of gene variants have 
been linked to differences in longevity in mammals, it will become feasible to systematically 
explore gene-by-environmental interactions, dissect mechanisms with more assurance, and 
evaluate the roles of epistasis and epigenetics in aging. A deeper understanding of complex 
networks—genetic, cellular, physiological, and social—should position us well to improve 
healthspan.
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Introduction
Over the past two centuries longevity has increased at an impressive rate, driven by 
innovations in sanitation, healthcare, nutrition, and social support [1–5]. The proportion of 
individuals who reach 95 has doubled in the past 25 years, and the peak age of death is now 
close to 85 worldwide [6]. In some populations there has also been a matched but more 
gradual increase in age of menopause by one year per decade since 1910 [7–8]. Further 
improvements in health care and social structure may push lifespan upward, but it is also 
possible that we are reaching fundamental biological constraints with diminishing prospects 
of healthy living beyond 100 years [9–10]. The same trends are replicated in laboratory mice
—60 years ago, mean lifespan of inbred strains averaged 488 days [11–12]. Genetically 
identical descendants of these strains now consistently live about 50% longer. This upward 
shift is almost certainly related to improved husbandry and low rates of infection.
As lifespan increases, causes of death shift from accidents and pathogens to late-onset 
chronic conditions such as cardiovascular, respiratory, and metabolic diseases, cancer, 
neurodegeneration, and adverse consequences of pneumonias [6, their Figure 3; 13]. In 
humans and other species this shift is a result of much weaker selection against heritable 
factors that reduce post-reproductive longevity—an insight dating back to 1881 [14]. George 
Williams refined this idea and argued that gene variants may have positive effects on fitness 
early in life but negative effects later in life: so-called antagonistic pleiotropy [15]. Humans 
and killer whales seem to defy antagonistic pleiotropy for two decades or more after 
reproductive senescence [16]. Even the roundworm, C. elegans, manages to extend lifespan 
at least twofold beyond the age of reproductive senescence [17]. There is countervailing 
evidence that post-reproductive vigor and lifespan in some species, including humans, is 
under positive selection and contributes significantly to fitness by enhancing the success of 
progeny [18–21]. This provides motivation to find factors that modulate the length of post-
reproductive healthspan. While we must continue to fight a rearguard action against age-
related chronic diseases, we need to focus much more attention on the deeper genetic, 
molecular, and cellular processes that modulate longevity, the main topics of this review 
[22–24].
Variation in longevity among species is pronounced and linked to life history and style of 
reproduction [18, 22, 25–27]. Weismann proposed that heritable differences driven by 
millions of years of natural selection are the root cause of this variation [14, 28]. He also 
pointed out that it was not possible for him “to indicate the molecular and chemical 
properties of the cell upon which the duration of its power of reproduction depends: to ask 
this is to demand an explanation of the nature of heredity—a problem the solution of which 
may still occupy many generations of scientists.” And so it has proved. We are still 
struggling to find and define genetic and molecular causes of aging [29–31]. Since the early 
1920s [32], we have known that gene variants influence longevity within species, just as 
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they must between species. But in humans and other mammals, discovering DNA 
polymorphisms (also known as chromosomal loci or gene variants) responsible for 
differences in lifespan has resisted standard mapping methods [early work reviewed by 28, 
33–34]. One pessimistic view has been that aging is a consequence of nearly random and 
irremediable process of stochastic decay driven by somatic mutations in both nuclear and 
mitochondrial genomes [35]. A more optimistic alternative is that differences in aging rates 
within species are modulated by genetic variants linked to metabolic states, accuracy of 
DNA repair, protein processing efficiencies, immune surveillance, and life history—what we 
and others call the deep causes of aging.
The difference is vital. If aging is fundamentally caused by stochastic molecular decay, there 
may not be good reasons to look beyond the most prevalent diseases to increase lifespan. In 
contrast, if longevity is largely a tunable genetic process, as the comparative biology of 
longevity indicates, then there should be room to push lifespan of humans well into a second 
century, not just by overcoming chronic disease but by more fundamental interventions that 
improve general health and vigor. Whether longevity is an integrated hazard function of 
many diseases or the result of deeper causes, it is not unreasonable to have a goal of good 
quality life to age 100 [36]—the age at which Jeanne Louise Calment finally put aside her 
bicycle [37]. She lived another 22.5 years.
Getting at the genetic basis of aging has been hard. We have succeeded in defining a small 
set of rare mutations in several genes such as LMNA, WRN, and SERPINE1 that model 
some aspects of aging and senescence [38–42], but these variants do not account for normal 
variability in longevity. Our main aim now is to uncover common sequence variants that 
influence the kinetics of aging. Many candidate genes have been nominated and tested based 
on their known roles in DNA repair and cell cycle control, mitochondrial function and 
metabolism, oxidative stress and proteostasis, and numerous other age-related processes 
[43–44]. These candidate gene studies often test for enrichment of specific alleles in old 
cohorts [27, 33]. While this approach may eventually fulfill its promise, hypothesis-driven 
tests of longevity linked gene variants have generally failed to replicate [45–46]. For 
example, a large and careful retest of three aged Danish cohorts came up empty-handed after 
surveying variants in 125 well known genes implicated in aging based on known molecular 
functions [47]. The conventional excuse for failures of this type is that longevity is a 
complex, multifactorial phenotype influenced by small contributions from many DNA 
variants (and of course, many environmental factors), making any one sequence variant 
exceedingly difficult to validate using simple association studies of this type [48–49]. 
Compounding this problem, methods are designed to detect only simple additive genetic 
effects. But there are good reasons to suspect that longevity is modulated by non-linear 
epistatic interactions, antagonistic pleiotropy [50], and gene-by-environmental interactions 
(GXE) among multiple loci and gene variants.
Insufficient statistical power is certainly one core problem [51–52], but thanks to rapid 
growth of elderly populations this should not be a problem much longer. Stepler estimates 
that there are now ~500,000 centenarians worldwide among a population of ~7.6 billion, and 
the expectation is that there will be ~3.5 million centenarians by 2050 [53–54]. Eighty-five 
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percent will be female [55]. We will soon have the access to the very large sample sizes 
needed to understand genetic and environmental control of longevity [56–58].
What is perhaps surprising is that many other traits that are arguably just as complex as 
longevity—in particular, metabolic and psychiatric diseases and traits such as body weight 
and height—have been mapped to numerous genes and loci. In these cases, however, 
mapping did not rely on the evaluation of small numbers of nominated candidate genes, but 
rather used unbiased genome-wide association studies (GWAS). As shown in Figure 1, these 
GWAS require unusually large sample sizes. For example, the analysis of height in humans 
did not relent to genome-wide analysis until cohorts exceeded 10,000 subjects. 
Schizophrenia is another good case study and a useful contrast to longevity. While the 
heritability of schizophrenia is high [59], the idea arose that spontaneous copy number 
variants were the primary cause [60]. The conundrum was solved by a very large GWAS 
[61]: with 37,000 subjects, a total of 108 single nucleotide polymorphisms (SNPs) were 
uncovered. While these SNPs have small effects, they have a significant combinatorial 
impact. The outcome has been a wealth of leads and unexpected mechanistic insight into the 
etiology of this complex disease [62].
With aging and lifespan studies, there is the added challenge of defining the most relevant 
phenotype. There are marked differences in methodology among studies [63], heterogeneity 
among populations [64–65], and unique genetic effects that may emerge only in extreme age 
[24, 36, 66]. In some cases, the approach has been to construct a phenotype amalgam based 
on different health and disease traits such as number of years free of major disease, or 
psychosocial and emotional functioning [49, 67]. The alternative of using lifespan (i.e., time 
to all-cause mortality) results in a heterogeneous and noisy phenotype. A complementary 
approach is to use multisystems measures of frailty [68] or molecular biomarkers. One 
example is the epigenetic status of specific regions of the genome that can be used as metrics 
of age in single tissues or cells [69]. Telomere length [42, 70–73], changes in metal isotopes 
[42, 74], and metabolites such as NAD+ [75–76] are other examples of molecular 
phenotypes of aging being validated in model systems and humans. These and other 
complementary assays are yielding interesting GWAS hits on what may be considered 
genetic roots of aging [77], but as has been emphasized by Birney and colleagues [78] it is 
sometimes difficulty to sort out genetic and environmental causes of aging from epigenetic, 
molecular, and cellular consequences.
In this status report on the genetics of longevity, we focus almost exclusively on forward 
genetic studies in mouse and human extending back to the dark ages of quantitative trait 
locus (QTL) mapping [79] and up to the first waves of GWAS in humans [24, 31, 80]. Our 
review revisits themes covered well by Yuan and colleagues [81]. A side-to-side comparison 
of our review with theirs is noteworthy and humbling. To give away the main conclusion, 
there has been painfully slow progress in defining and validating common or rare variants 
that modulate longevity in mouse or human. We weigh in favor of the simple explanation: 
that the paucity of longevity hits is primarily the result of inadequate sample size rather than 
a fundamental problem related to genetic control (or lack thereof) of lifespan. As shown in 
Figure 1, samples of hundreds of thousands of cases may be mandatory for high yield 
analysis of the genetics of longevity in humans. As we will see below, the size of mouse 
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cohorts can be much smaller since almost all studies make use of families of closely related 
cases or even sets of isogenic strains. GWAS have high mapping precision but low power 
(hence the need for large sample sizes), while studies using rodents generally have modest 
mapping precision (1 to 10 Mb) but relatively high power. By combining results from both, 
we can gain both power and precision to detect gene variants associated with longevity—an 
approach that has been highly effective in other areas of research [82–84].
Two studies published in 2017 provide an empirical basis for optimism. Both took unusual 
approaches to the problem: McDaid and colleagues [31] used statistical methods to remove 
confounds associated with age-related diseases and used very large samples sizes via the UK 
Biobank; Sebastiani and colleagues [24] accomplished the same goal by studying extremely 
long-lived humans—so-called supercentenarians—using more modest sample size. Both 
studies nominated candidate genes and loci that may get at the deep metrics and mechanisms 
of aging in mammals, and certainly in humans. These variants, in turn, should provide 
reagents and motivation to dissect molecular controllers and biomarkers of aging, ultimately 
explaining some of the intrinsic sources of variation in longevity. Genomic methods of 
mapping and validating DNA variants are becoming so powerful and efficient, and sample 
sizes so large, that we should soon be able to resolve large numbers of longevity modulators. 
We should then also be able to move to the opening of Act 2—the analysis of GXE.
Heritability of longevity
Estimates of the heritability of longevity are generally low. Values average about 20% but 
range widely—from close to 0% to as high as 50% in most natural populations of yeast, 
nematodes, butterflies, fruit flies, deer, bighorn sheep, and humans [17, 28, 85–89]. 
Estimates from human cohorts typically hover around 20–30% with heritability increasing 
among families with exceptional longevity [36, 90–91]. Age at menopause, the best metric 
of reproductive aging in humans, has a heritability that is significantly higher—about 60–
65% [92]. Heritability of traits is often an inverse function of their importance to survival 
and fitness—the more important a trait, the more it will be scrutinized by natural selection, 
and the lower its heritability [87; but see counterpoints by 89]. There is an unfortunate 
tendency to equate heritability with tight genetic control, and to equate genetic control with 
molecular control. Neither is correct. Traits that are key to survival and fitness are obviously 
under genetic, molecular, and cellular control—numbers of arms and legs being a silly but 
useful case in point. But for many key life history traits, the statistical definition of genetic 
control measured by heritability can be exceedingly low. This finding implies that DNA 
variants have been sanded smooth by selection and that residual sources of variability in 
longevity are mainly caused by environmental factors or cellular stochastics. There are 
exceptions to this rule, mainly in the form of balancing selection, but the low heritability of 
longevity should probably be interpreted as a sign that selection is actively filtering DNA 
differences that change rates of growth, reproduction, parental investment, and aging. Again, 
the dramatic variation in longevity among closely related species leaves little room for 
argument [22, 25, 93].
Heritability of longevity is not a fixed parameter even within a single species or age cohort. 
Estimates are sensitive to GXE, sex, and even—almost paradoxically—the age of the cohort. 
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Harsh or volatile environments that increase the range of variation in lifespan will tend to 
increase heritability estimates. The range of ages over which heritability of longevity or 
hazard ratios are computed is also an important parameter. Studies of twins demonstrate that 
the likelihood of survival (or conversely, the risk of death) increases with the age of the 
cohort, as does the heritability. This makes sense if we consider two extremes. On the one 
hand, young individuals who have just become sexually mature should have a risk of death 
that is determined largely by environmental factors or bad luck, not by gene variants. At this 
stage of maturation, human monozygotic and dizygotic twins do not differ much in their risk 
or survival concordance [94]. On the other hand, individuals older than 60 will have a risk of 
death that is determined to a progressively greater degree by genetic influences on rates of 
senescence and risks of chronic disease. Above 60 years-of-age, hazard ratios of 
monozygotic twins are much more similar to each other than those of dizygotic twins [94].
Nor is heritability necessarily fixed even with a given set of genomes and environment. 
Heritability can be boosted by using large families of inbred or isogenic lines and can easily 
be raised to 30–50% by resampling the same genome many times [79, 95–96]. We have used 
data from two recent longevity studies of mice—that of Yuan, Bogue, and colleagues [12, 
97] and our own ongoing study of the BXD strains [98]—to compute heritabilities of 
longevity based on strain means. Estimates range from 25 to 45%, extending up to 55% in 
the case of BXD females placed on a high fat diet. Goodrick [99] and Rikke and colleagues 
[96] provide an even higher estimate—up to 85% for the effective heritability of strain 
means [100].
Collectively, these estimates of heritability of longevity in panels of inbred strains of mice 
are much higher than those for other species—from yeast to human—for three reasons: (1) 
tight control of the environment and food sources, and negligible pathogen exposure; (2) 
longevity is computed as a mean, median, or hazard function based on large numbers of 
genetically identical cases (usually 5 to 20 samples/genome); and (3) families of fully inbred 
strains collectively incorporate twice the genetic variance of outcrossed populations because 
they lack heterozygous loci [101]. With sufficiently deep resampling of isogenic cohorts, the 
effective heritability of longevity can be pushed surprisingly close to 1.0 in a well-controlled 
environment. The ability to boost heritability in these ways makes families of inbred strains 
a welcome complement to studies of more complex outcrossed natural populations, 
including humans. It also means that relatively small sample sizes may be effective in 
mapping longevity loci.
In addition to achieving high heritability and high power with relatively modest sample 
sizes, it is also possible to use families of inbred strains or isogenic lines to study biomarkers 
of aging under many different, but tightly controlled diets, treatments, and stressors [96, 98, 
102]. But there are also disadvantages of using inbred strains in longevity studies, the 
foremost being that individuals are homozygous across their entire genome. While this 
increases the genetic variance, it may also increase the burden of diseases influenced 
strongly by recessive alleles. This could in principle compromise average longevity 
compared to either outbred populations [103] or four-parent F2 intercross progeny of the 
type used in the Interventions Testing Program [104–107]. However, at least in the case of 
the LXS family of mice that has been so well characterized in several different environments 
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[96, 102], the family of inbred strains manages to live to an average age of 825 days (44 
strains), and some strains live to an average of 1200 days even on a conventional unrestricted 
diet (e.g., LXS46). This lifespan rivals that of dwarf mice on caloric restriction [108], and is 
exceeded only by a handful (literally) of Ghr knockout mice [109] and outbred mice. For the 
record, the current record age reached by any mouse is an individual from the Diversity 
Outbred population that reached 1730 days (Dr. Steven Munger, personal communication).
What happens to the heritability of longevity after the reproductive phase of life? 
Antagonistic pleiotropy [15] posits that alleles that have positive effects on growth and 
reproductive success early in life may accelerate senescence after reproduction [110]. In 
contrast, alleles that slow growth and reproduction may increase lifespan as well as 
sensitivity [111] or resilience to stress [112]. Following in the footsteps of Weismann, there 
is also evidence of direct competition between the germline and somatic tissues that can 
shorten or extend life [113–115]. In contrast, there is not much direct evidence for 
antagonistic pleiotropy in humans, although the APOE gene is a reasonable candidate [116–
117], and sex hormone genes also may fall into this category—essential for reproductive 
performance but with deleterious effects when expressed later in life [118]. There may be 
countervailing pressure that has to do with persistent parental and grandparental investment 
in the fitness of progeny [18–19, 21]. There are also good reasons to suspect that plasticity 
of life history traits, such as age of reproduction and peak parental investment, will be under 
strong balancing selection in a normally volatile world with many ecological niches for 
single species [119]. Even in the absence of antagonistic pleiotropy, selection will inevitably 
be relaxed after the main phase of reproduction, and this will contribute to the steep increase 
in incidence of chronic diseases and the steep rise in mortality described by Gompertz nearly 
200 years ago [120]. The good news is that this steep rise in mortality should be 
accompanied by a steep rise in heritability, implying that conscious attention to both alleles 
and environments should enable significant enhancement of healthspan.
In conclusion, the heritability of longevity is low compared to that of most chronic diseases, 
and even traits such as height, body weight, and schizophrenia. This low heritability goes a 
long way to explaining the comparative difficult of mapping longevity, a finding highlighted 
well by the longevity points we have added in Figure 1. In humans, very large sample sizes 
will generally be required (hundreds of thousands of centenarians would be ideal). But as we 
show in the next section, when working with families of isogenic strains, cohorts of as few 
of 30–40 have proved effective [79, 96, 102, 121–122] because heritability can be 
maximized.
Mapping longevity loci in mouse
Mice are the preeminent mammalian model of aging. Reasons are simple—an impressive 
wealth of genetic and genomic resources and tools [97, 123–124], coupled with small size, 
fast reproduction, short lifespan, high tolerance for inbreeding, and of course, an impressive 
set of methods to modify genomes [125–127]. These many advantages enable extensive and 
detailed investigation into both the genetics and the molecular biology of aging—from the 
first studies of lifespan by Roderick and Storer [11] to the latest studies from the 
Interventions Testing Program (ITP) [128]. Mice, like other mammals, share ~95% of 
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protein-coding genes with humans [129], but their much shorter lifespan makes longevity 
studies practical [e.g., 96, 102]. This latter factor is critical in efficiently mapping loci, and 
even DNA variants, influencing lifespan and aging as a function of experimental 
manipulations [81, 104, 107, 130].
A range of murine resource types have been used to map variation in longevity. The first 
study by Smith and Walford used a panel of congenic strains on a C57BL/10 background 
that harbored different versions of the major histocompatibility (MHC or H2) locus on 
chromosome (Chr) 17 [130]. Yunis and colleagues analyzed longevity in a conventional 
backcross [79] and then followed up with an analysis of longevity across 20 BXD 
recombinant inbred strains [121]. More recently, an expanded panel of BXD strains (n ~ 75) 
has been used in a second phase of longevity studies investigating two diets—6% versus 
60% calories from fat [131]. Rikke and colleagues have also used the LXS recombinant 
inbred strains, in their case derived from a cross between ILS and ISS parental strains [96]. 
They also used matched sets on two diets—a conventional ad libitum diet or an intense 
dietary restriction. Surprisingly, few studies have used standard F2 intercrosses to map 
longevity in mice [132–133], the main challenge being able to achieve sufficient power 
using an intercross in which every case is genetically unique. But sample sizes of more than 
1000 intercross progeny, heterogeneous stock, or outbred mice should soon yield results.
By far the largest and most systematic study of lifespan variation in mice is the ITP, a 
resource that is ideal for mapping QTLs for longevity. The ITP was initiated in 2004 [104, 
134–135] and has made use of an intercross between C57BL/6J x BALB/cByJ F1 females 
and C3H/HeJ x DBA/2J F1 males [136]. Each of the F2 progeny is genetically unique, and 
this does impose design limitations, but the benefit is excellent consilience with human 
populations. The F2 mice generated by the ITP have been used primarily for non-genetic 
studies of the impact of dietary interventions on lifespan [107, 128, 137–138]. For example, 
smaller F2 progeny tend to live longer than larger siblings, and have lower levels of thyroid 
hormone T4, growth hormone mediator IGF1, and leptin [139]. A small cohort of these F2 
animals was used in an early mapping study of longevity [132], but in an era when marker 
resources were modest. The ITP cohort is now so large (n ~15,000 cases) that it is now well 
powered to detect longevity QTLs [98].
How replicable are results from longevity studies using mouse models? Longevity estimates 
generated by Roderick and Storer [11] correlate well with data generated 48 years later by 
Yuan and colleagues (r = 0.88), although lifespan increased from 520 to 754 days. Gelman 
and colleagues [121] studied longevity in 15 strains in common with Lang et al. [140], and 
again the correlation is high (r = 0.77). In this case, longevity values also replicate (Gelman 
et al.: 711 days, n = 23 strains, all females; Lang et al.: 704 days, n = 23 strains, all females). 
Differences in longevity between sexes can be large [141]. The correlation of male-female 
lifespan in Lang’s study of the BXD strains is 0.40, and males actually outlived females by 
two months. The ITP has shown that longevity of males is particularly sensitive to housing 
despite best efforts to standardize husbandry [106, 137–138]. Finally, dietary interventions 
can completely disrupt patterns of longevity. Correlations across the LXS strains on 
restricted or unrestricted diet are merely –0.02 and 0.15 for females and males, respectively 
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(n = 41 strains, median longevity). In sum, we should be prepared for potentially strong 
environmental and sex effects on longevity.
Over the past four decades, 16 studies have been carried out to define QTLs for longevity in 
mice—a surprisingly modest number given the importance and inherent interest of this topic 
[79, 96, 121–122, 130, 132–133, 140–148]. The first genetic analysis by Smith and Walford 
[130] exploited congenic strains and very large sample sizes (n = 120 per congenic strain) to 
test whether longevity is modulated by sequence variants in the major histocompatibility 
complex (MHC, H2) on Chr 17. The answer in this study was yes, but as the authors point 
out, longevity linkage results will depend strongly on the environment. Genotypes in this 
critical region controlling the adaptive immune response after infection should be a 
determinant of longevity when pathogen levels are high. Standards of animal care have 
changed greatly over the past 40 years—in particular, the introduction of specific-pathogen-
free colonies. To the best of our knowledge, none of the more recent studies have detected a 
longevity locus on Chr 17.
In several cases, different cohorts made using the same parental strains have been used 
repeatedly to refine longevity QTL maps. The best example of a progressive improvement in 
power and precision is work that has been carried out since 1979 using C57BL/6J (B6) and 
DBA/2J (D2) parental strains and their progeny. The first analysis of longevity by Yunis and 
colleagues [79 1984] preceded the introduction of modern genetic mapping resources, and 
the authors were able to test only three markers in a backcross of 388 cases (Figure 2). 
Remarkably, two of their markers were highlighted as predictors of differences in longevity. 
Only one of these would now be considered significant after corrections for multiple tests—
that linked to the brown locus, Tyrp1, on Chr 4. Gelman and colleagues [121] replicated this 
longevity analysis within the same laboratory, but now using BXD recombinant inbred 
strains also made by crossing B6J to D2. With a more comprehensive set of 101 markers, 
they linked variation in lifespan to loci on Chrs 1, 2, 7, and 12, but did not confirm linkage 
to Tyrp1 (Figure 2). de Haan and colleagues [143] revisited Gelman’s data after noticing a 
curious distribution in the range of lifespan within isogenic strains: high variation in age of 
death in nine strains, moderate variation in seven strains, and low variation in eight strains. 
Using this new phenotype they were able to map a locus on Chr 11 that may control 
variability of longevity within strain (Figure 2). These traits can now be remapped in 
GeneNetwork (www.genenetwork.org) simply by linking to the appropriate BXD phenotype 
trait identifier. For example, the longevity variability data is listed in GeneNetwork as BXD 
phenotype trait 19422, and it is easy to validate the Chr 11 locus. Using the latest genotypes, 
this trait has a linkage peak with a logarithm of odds (LOD) score of 4.8 between Meis1 
(unc-62) to the exportin 1 gene, Xpo1. Both genes are strong biological candidates [149–
150]. One caveat: the statistic that they used—range of lifespan within strain—is an unusual 
and noisier trait than conventional longevity statistics, such as the mean or median lifespan. 
It will soon be possible to test whether this trait can be replicated in much larger BXD aging 
cohorts.
Lang and colleagues [140] also generated independent longevity data for 23 BXD strains—
17 common to Gelman—and they report a QTL on Chr 7, as well as a locus on Chr 11 for 
median lifespan (Figure 2). We have not been able to replicate their results at a genome-wide 
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significance level using much higher densities marker maps (see GeneNetwork BXD 
phenotype traits 12563 and 12564). We suspect that the map method that they used—
composite interval mapping—explains this failure. This method is generally not 
recommended with such small sample size, because it is easy to test too many alternative 
models.
Finally, Houtkooper and colleagues [122] remapped the Gelman BXD longevity data 
(GeneNetwork BXD phenotypes 17475, 10148, 10112) but now using 3800 markers and 
treating outlier data appropriately for mapping. They were able to refine the initial Chr 2 
locus to a comparatively short interval of about 5 Mb (see GeneNetwork BXD group trait 
17475). Validation studies of genes in this interval using C. elegans and mouse aging 
transcriptome data sets highlighted the mitochondrial ribosomal protein S5 (Mrps5) as the 
single best candidate. Inactivating this gene in worm extended lifespan significantly and also 
triggered a mitochondrial unfolded protein response (UPRmt). While linkage between a 
specific sequence variant in mouse and direct control of lifespan is still not yet established, 
our working hypothesis is that sequence differences near Mrps5 influence the UPRmt and 
thereby longevity. The role of this family of mitochondrial genes in human longevity is an 
open question, but there is evidence that the mitochondrial ribosome—consisting of about 
74 protein coding genes in all—is associated with differences in neurocognitive aging in 
older women [151].
The LXS panel of recombinant inbred strains has also been used effectively and 
collaboratively to map longevity QTLs. Liao [102] and Rikke and colleagues [96] aged mice 
at two sites and collectively have defined loci on Chrs 7, 9, and 15 affecting lifespan, 
fertility, and metabolic efficiency in response to dietary restriction. None of these loci has 
yet been linked to genes or mechanisms, but the Chr 15 locus has been fine-mapped to a 
small interval using congenic strains [152]. One concluding note on current mouse longevity 
QTL data: it is now practical to remap and reanalyze many of the older data sets using 
GeneNetwork [124]. For example, while the first wave mapping studies used up to 1000 
markers [96, 140], it is now possible to remap both BXD and LXS longevity data using far 
denser and more reliable maps. Remapping was the first step that led to the discovery of 
Mrps5 by Houtkooper and colleagues [122]. As part of this review, we remapped all 
longevity traits in Rikke et al. [96] and now detect an apparently new female longevity locus 
(normal ad libitum diet) on Chr 1 at about 80 Mb (Figure 2, and see GeneNetwork LXS 
group, trait 10156).
Mapping longevity gene variants in humans
While interest in genetic determinants of longevity in humans has grown significantly as 
gene mapping methods have become more powerful, there are still comparatively few 
robustly mapped, replicated natural variants that modulate longevity. Only the TOMM40/
APOE/APOC1 gene cluster (19q13.11–19q13.32) and the FOXO3 gene (6q21) can make 
this claim [46, 91, 153–154]. Apolipoprotein E (APOE) has two isoforms known to 
influence longevity through their association with disease, APOE ε2 and APOE ε4 [48]. 
APOE ε2 promotes longevity largely by decreasing risk of cardiovascular disease and 
Alzheimer disease whereas APOE ε4 does the opposite, limiting longevity [155–158]. 
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Similarly, the ε2 allele is enriched in centenarians whereas the ε4 allele is diminished [159–
160]. Inheriting two copies of the APOE ε4 allele reduces the odds of achieving exceptional 
longevity by 45–65% [161]. The effects of these isoforms are robust and have attained 
genome-wide significance in at least 10 human GWAS studies of longevity and age-related 
disease (Table 1). Interestingly, recent work has shown the ε4 isoform may be beneficial in 
non-industrialized settings [116–117]. The forkhead box O3 (FOXO3) gene has a more 
modest association with longevity but has also crossed the significance threshold in a recent 
GWAS [153]. FOXO3 is linked to insulin/insulin-like growth factor 1 signaling [162–163] 
and is a compelling true longevity gene. Other than APOE and FOXO3, there are also a 
number of candidates that are statistically significant, but not yet validated (Table 1). These 
include GRIK2 [153], RAD50/IL3 [164], and MINPP1 [80].
A recent study by McDaid and colleagues [31] developed a new approach to discover 
longevity loci. They took advantage of the many SNPs linked to age-related disease and 
adjusted for these effects to detect underlying polymorphisms that modulate lifespan. The 
team was able to use an exceptionally large general population cohort rather than focusing 
on only the oldest of the old. Sixteen SNPs were highlighted as genome-wide significant and 
11 were replicated in five independent cohorts. This study is also one of the first to bridge 
between mouse and human longevity data. Gene expression in the LXS mice was analyzed 
to evaluate the three strongest human candidate genes—RMB6, SULT1A1, and CHRNA5. 
Increased lifespan was associated with lower mRNA levels of RMB6 in mouse prefrontal 
cortex. A caloric restricted diet known to extend lifespan in mice was associated with 
increased SULT1A1 expression. These joint approaches using data from several species has 
promise to define new loci.
The point of mapping gene variants that control longevity is to use them as validated entry 
points to defining mechanisms of aging—the topic of next section. While mapping is not a 
necessary prelude to studying mechanism, it has the advantage of being relatively unbiased, 
and can help find common gene variants that are modulators of lifespan and healthspan. A 
complementary and powerful approach is to systematically inactivate genes one at a time 
across the genome [165]. This approach has been most effective in small organisms such as 
yeast, nematode, and fruit fly. For example, Magwire and colleagues [111] used transposon 
mutagenesis to define 58 loci that increase longevity (on average about 12%) in Canton-S 
derived isogenic lines. They defined many non-linear interactions among mutations and 
significant differences between sexes. There are two minor downsides to this approach. First, 
most experiments of this type test mutations on one genetic background, which will limit 
generality of specific gene effects. Second, induced mutations can inactivate genes 
effectively, but they are unlikely to replicate the effects of natural variants for longevity that 
are likely to be under intense selection.
From mapping to mechanisms
One of the major goals of aging research is to understand mechanisms well enough to reduce 
age-related disease burden, improve vigor, and extend healthspan and lifespan. As 
mentioned above, mapping does not get us there; it just points— we hope—in the right 
direction. We know a great deal about the molecular and cellular biology of longevity from 
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classical experimental approaches in model organisms that we outline below. But the point 
of this section is to encourage thought about how to effectively bridge between two major 
approaches to longevity—the highly effective reductionist paradigm and the more holistic 
and unbiased systems genetics approach. The reductionist approach looks for large effects of 
mutations and perturbations using constrained experimental designs (usually one genotype); 
the systems approach uses a more open-ended discovery design and large genetically 
complex cohorts. We need to bridge between these approaches, their communities, and most 
importantly, their key discoveries [166]. QTLs and GWAS hits for longevity need to be 
combined with everything we know about mechanisms of longevity. Mapping longevity 
should ideally not be unbiased, but should take advantage of all of the prior information we 
have on disease process and normal aging in all organisms.
Model organisms have been vital to this goal of identifying and understanding the molecular, 
cellular, and environmental factors affecting longevity and thereby improving lifespan. 
Studies in S. cerevisiae [167], C. elegans [168–169], D. melanogaster [111, 170], and most 
recently killifish [171] have all made major contributions toward understanding mechanisms 
that modulate longevity. An in-depth discussion of all these evolutionarily conserved 
biological processes and factors is beyond our scope; instead we refer readers to 
comprehensive overviews by Kenyon [172], Houtkooper and colleagues [173], López-Otín 
and colleagues [174], and Riera and colleagues [175].
In the following short sections, we enumerate some of the major intertwined mechanisms of 
senescence and longevity along with sets of gene variants highlighted in genetic studies.
1. Nutrient-sensing pathways that regulate aging
Insulin/IGF-1 and FOXO pathway—The first and possibly best characterized pathway 
to influence aging in organisms ranging from yeast to mammals is the insulin/IGF-1pathway 
[172, 176]. Extensive research has shown that cumulative regulation of many genes through 
DAF-16, a FOXO transcription factor; HSF-1, the heat-shock transcription factor; and 
SKN-1, a Nrf-like xenobiotic response factor in the insulin/IGF1 signaling pathway prolongs 
the lifespan of C. elegans and Drosophila melanogaster by as much as two-fold [reviewed by 
172]. In mammals, the relation between insulin/IGF1 signaling and longevity becomes more 
complex owing to the involvement of multiple insulin and IGF receptors, and because of the 
crucial role for insulin in regulation of glucose homeostasis. The insulin/IGF-1 pathway is a 
good candidate for mediating longevity through dietary restriction in worms, flies, and mice 
under specific conditions [177].
While polymorphisms in many core genes in these extended networks have been tested 
repeatedly [e.g., 47], most do not control normal variation in longevity in human 
populations. In humans, only variants in the FOXO3 gene have been consistently replicated 
as associated with longevity across multiple populations, with the minor allele AA genotype 
being associated with increased lifespan [153, 178].
TOR signaling—The mechanistic target of rapamycin (mTOR) is a serine/threonine 
protein kinase that functions in two distinct complexes regulating different downstream 
processes—mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [179]. Under 
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conditions favorable for growth, TOR signaling modulates protein translation, protein 
homeostasis, and cellular growth and has been implicated as a controller of longevity in 
diverse species. Interest in understanding the physiological role and molecular targets of the 
TOR pathway has surged since the discovery that rapamycin treatment extends life in yeast, 
nematodes, flies, and mice via mTOR inhibition [180]. The TOR network has also been 
consistently linked to dietary restriction that reduces mTORC activity, which in turn 
increases lifespan in many organisms ranging from yeast to mice [172]. Sataranatarajan and 
colleagues report that rapamycin shortened the lifespan of the leptin receptor db mutant 
mouse—a reminder that genes and the networks they influence are unlikely to be universally 
beneficial [181]. Selman and colleagues showed increased lifespan in a mouse model of 
decreased mTOR signaling —ribosomal S6 kinase 1 knockout mice (S6k1−/−) [182]. 
Similarly, mTOR knockout strains (Mtor+/− and Mlst8+/−) and hypomorphic homozygous 
MtorΔ/Δ mice have increased lifespans [183–184]. mTORC1 promotes mRNA translation 
and protein synthesis by activating ribosomal protein S6 kinases (RPS6KA1) and inhibiting 
eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) [179]. However, no 
associations have been detected yet for mTOR complex gene variants (MTOR, RPTOR, 
RICTOR, and RPS6KA1) with extreme human longevity [185].
Sirtuins—Sirtuins, a protein family of metabolic sensors, have gained recognition over the 
last two decades as crucial regulators of evolutionary conserved pathways related to aging in 
a wide variety of organisms ranging from yeast to mammals [186]. The role of sirtuins in 
aging was first identified in yeast [187]. Since then, several research groups have showed 
that Sir2 overexpression in C. elegans [188] and Drosophila [189] results in extending 
lifespan in a dose-dependent manner. Mammals have seven homologs of the yeast Sir2 gene 
(SIRT1 to SIRT7). All homologs contain the highly conserved NAD-dependent sirtuin core 
domain. This domain targets multiple cellular substrates and influences a broad range of 
cellular functions, including multiple metabolic and neuronal pathways. Experiments in 
mouse have shown that sirtuins are modulated by diet; thus, sirtuins could be therapeutic 
targets to enhance healthspan [190]. SIRT1, the best-characterized mammalian sirtuin, 
controls mitochondrial function by deacetylation of targets like TRP53, PPARGC1A, and 
FOXO [191]. There is compelling evidence that enhancing sirtuin activity leads to decreased 
cancer risk and is protective against metabolic dysfunction associated with aging [191–192]. 
SIRT3, which localizes to mitochondria, appears to be required for dietary restriction–
mediated longevity through deacetylation of mitochondrial proteins [193]. SIRT6 is a key 
modulator of healthy aging, and mice deficient in SIRT6 have a reduced lifespan. 
Overexpression promotes genomic stability [194], promotes DNA repair, and suppresses 
genomic instability [195]. Deficiencies in mice lead to age-associated degenerative 
abnormalities and early death.
Lack of lifespan extension in Sirt1−/− mice on caloric restriction, as well as the paucity of 
associations between polymorphisms in SIRT1 and human lifespan, has cast doubts on the 
relevance of SIRT1 as a key longevity gene [196]. Association studies of of lifespan and 
SIRT3 are inconsistent [197–199]. In the Iowa cohort of the Established Population for 
Epidemiologic Studies of the Elderly, homozygous minor allele TT genotypes for SIRT5 and 
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SIRT6 were associated with a shorter lifespan, after controlling for age-related risk factors 
[200].
AMP kinase signaling—SIRT1 and AMPK are co-regulated; they interact and share 
many common target molecules. AMPK (adenosine monophosphate-activated protein 
kinase) is a highly conserved cellular energy sensor that is activated when cellular energy 
reserves are low, and also maintains metabolic energy balance [201]. AMPK is a key 
mediator of several signaling networks linked to aging and is activated by a wide array of 
small molecules, making it a potential therapeutic target for pro-longevity drugs such as 
metformin, resveratrol, rapamycin, aspirin, as well as a key mediator of several signaling 
pathways linked to aging [202–203]. However, many of these effects are indirect and are yet 
to be fully elucidated by work in model organisms. AMPK activity may be an important 
contributing factor in networks linking autophagy [204], dysregulated intracellular lipid 
metabolism, and reduced mitochondrial function associated with aging [205]. AMPK 
activity controls the function of several signaling networks associated with aging: FOXO/
daf-16 [172, 206], SIRT1 [207], TOR [179], and CRTCs [208]. AMPK-induced 
deacetylation by SIRT1 modulates the activity of downstream targets, including the 
peroxisome proliferator-activated receptor-γ coactivator 1α (PPARGC1A) and the forkhead 
transcription factors, FOXO1 and FOXO3. Treatment of mice with resveratrol, famously 
linked to cardiovascular benefits and cancer preventive properties of red wine, activates the 
NAD+–SIRT1 network and induces genes impacting oxidative phosphorylation and 
mitochondrial biogenesis [209]. The beneficial effect of S6K1 deficiency on lifespan might 
involve AMPK activation [182].
2. Mitochondrial function and reactive oxygen species effects
A decline in mitochondrial function contributes to normal aging through multiple distinct 
processes, including oxidative damage, inflammation, and senescence [210]. Reactive 
oxygen species (ROS), generated as a by-product of the mitochondrial respiratory system 
and intracellular metabolism in peroxisomes, were initially implicated as one of the 
causative factors of aging. Increased ROS levels may be detrimental and lead to cell death 
and acceleration in aging and age-related diseases; genetic studies in C. elegans, Drosophila, 
and mice have implicated enhanced stress resistance or reduced free radical production with 
increased lifespan [211]. Senescent cells are associated with high levels of intracellular ROS 
and accumulated oxidative damage to DNA and proteins [212]. However, that theory has 
been largely refuted, and several studies have shown that mitochondria can cope with 
physiological levels of oxidative damage [213–216]. Such ROS levels are most likely 
essential for regulation of cell cycle progression, cell signaling, and apoptosis, while 
increased ROS production over a certain level has a detrimental effect on cell physiology 
[217–218]. Lifespan extension by mild inhibition of mitochondrial respiration is 
evolutionarily conserved. Some key factors required to mediate this longevity response 
include dietary restriction, increased HIF1 activity, induction of homeobox protein CEH-23, 
and mitochondrial unfolded protein response (UPR) [219]. Impairment of the mitochondrial 
translation by a drop in mitochondrial ribosomal protein S5 (MRPS5) level initiates UPRmt 
activation and results in increased longevity in both worms and mice [122].
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Many of the longevity genes, including AKT (glucose uptake), EIF4EBP1, and RPS6KA1 
(protein synthesis, autophagy), SIRT (mitochondrial function), and FOXO3 (oxidative stress 
defense), have multiple effects with intertwined actions in overlapping metabolic networks 
that often affect mitochondrial function [173]. Associations between mtDNA and longevity 
differ from the SNP-based associations seen in the nuclear genome. Several small and 
underpowered studies have associated mtDNA variation with human longevity in Japanese 
[220], Chinese Uygur [221], Italian [222], French [223], Irish [224] and Finnish [220] 
populations.
3. DNA damage and genomic instability
Perturbations in genomic stability might have negative outcomes, including cancer, reduced 
lifespan, and premature aging. Genomic DNA is subjected to incessant chemical, physical, 
and biological abuse, resulting in tens of thousands of molecular lesions per cell per day 
[225]. DNA damage can result from endogenous processes, such as hydrolysis, oxidation 
and alkylation, or exposure to radiation or environmental mutagens. Most DNA lesions are 
rapidly corrected by a sophisticated network of genome maintenance systems. Unrepaired 
DNA damage, both nuclear [226] and mitochondrial, leads to mutations, loss and gain of 
sequence, and aging [227–228]. The RecQ helicase family participates in maintaining 
genomic stability and is conserved across organisms [229]. In humans, sequencing of genes 
involved in DNA repair revealed that SNPs in the WRN helicase gene are associated with 
shorter lifespan. GWAS studies have identified markers associated with longevity at loci 
involved in genome maintenance, including WRN, LMNA, CDKN2A/CDKN2B, FOXO1, 
and FOXO3 [41, 230].
4. Proteostasis imbalance
Protein homeostasis is maintained by tightly regulated action of intricate cellular systems 
that are gradually compromised with age, leading to an increase in accumulation of damaged 
and misfolded proteins. Loss of proteostasis contributes to many age-related pathologies, 
including neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease [231]. 
Most cellular proteins fold directly after translation in the cytosol while membrane and 
secreted proteins fold in the endoplasmic reticulum. Presence of misfolded proteins in these 
cellular compartments is detected by chaperone networks, which initiate a proteostasis 
response to restore cellular homeostasis. The cytosolic response is initiated by the heat 
shock response (HSR) regulated by stress-activated heat shock factor1 (HSF1) which 
induces transcription of chaperones and other protective genes [232]. In worms, reduction of 
HSF1 induces accelerated aging. In response to endoplasmic reticulum (ER) stress, unfolded 
protein response UPRER is mediated by three signaling cascades modulated by IRE1, PERK, 
and ATF6, leading to several outcomes including reduced translation rates and 
transcriptional upregulation of many chaperones [233]. Prolonged stress triggers apoptosis. 
In mitochondria, both the integrated stress response and UPRmt are activated to protect from 
proteotoxic stress, initiating a mitonuclear cascade that leads to transcription of protective 
genes [234–235]. Damaged proteins are degraded by the two principal proteolytic systems: 
the ubiquitin–proteasome system and the autophagic–lysosomal system. Their efficiency 
declines with age, supporting the idea that protein clearance mechanisms are directly linked 
to aging and age-associated diseases [236].
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Activation of UPRmt correlates with longevity across organisms in yeast, worms, flies, and 
mice [237]. A QTL for lifespan on Chr 2 in the BXD family of mice is thought to 
correspond to polymorphisms in mitochondrial ribosomal protein S5 (Mrps5). Expression 
correlates inversely with longevity in mouse, as it does in C. elegans [122]. Although no 
association has yet been found between mitochondrial ribosomal proteins (MRPs) and 
human lifespan, pathway-level genetic analysis points toward association between the MRP 
family and cognitive decline in women, independent of the APOE locus [151] and protein 
aggregation in C. elegans [238].
5. Telomere length
Telomeres are complex nucleoprotein structures at the tips of eukaryotic chromosomes made 
up of repetitive sequences bound by shelterin complex proteins (TRF1, TRF2, TIN2, POT1, 
TPP1, RAP1) [239]. The erosion of telomeres during DNA replication can trigger the onset 
of cellular senescence [240], but linkage between telomere length, aging, and reproductive 
success are complex and depend on species and life history [e.g., 241]. Common laboratory 
strains such as B6 mice have a mean telomere length of ~50 kb, whereas the wild-derived 
CAST/EiJ has shorter (~15 kb) telomeres comparable to that of humans [242]. Telomere 
length is inherited as a unique genotype, and short telomeres are sufficient on their own to 
cause degenerative diseases associated with aging even in the presence of normal levels of 
telomerase [243]. Heritability of telomere length has been demonstrated in human studies, 
but it is still unclear whether telomere shortening is a risk factor for telomere-mediated 
disease [244].
The most prevalent genes implicated in monogenic inherited telomere disorders (about 90% 
of cases) are TERT (telomerase reverse transcriptase) and TERC (telomerase RNA). Rare 
mutations in these genes cause autosomal dominant disease leading to significant morbidity 
after maturity [42, 245]. Taking a candidate gene approach, Atzmon and colleagues 
identified a common TERT haplotype that is associated with both exceptional longevity and 
telomere length in a cohort of Ashkenazi centenarians and their offspring [246]; a finding 
that has been replicated with variable success [247, see, http://genomics.senescence.info/
longevity/gene.php?id=TERT)..
6. Epigenetics
There is no doubt that the epigenome ages at multiple levels (e.g., histones and 
heterochromatins, noncoding RNAs, DNA methylation) [248–250]. DNA methylation has 
received the most attention because this modification can be most readily quantified by 
existing technology. The most widely used epigenetic clock is calculated using 353 specific 
CpG sites that are distributed across the human genome, and this age biosignature has been 
more closely related to “biological age” rather than “chronological age” and is predictive of 
human health and longevity [251–253]. This powerful approach for predicting the biological 
aging rate has now been extended to mouse [254].
The mechanistic basis of epigenetic changes as a function of age remain unclear. Genetic 
variation is causally linked to phenotypes, but interpreting associations with epigenetic 
markers can be problematic. Unlike GWAS hits, the direction of causality between DNA 
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methylation and aging is ambiguous [78, 255]. Epigenetic data are also more liable to noise 
and confounding variables; for instance, the increase in cellular heterogeneity with aging 
could contribute to some of the age-related signal in DNA methylation. An optimal scenario 
would be when evidence from both genetic and epigenetic studies converge on a common 
gene variant that modulates the epigenome. A possible example is the enhancer of zest 
homolog 2 (Ezh2) gene that codes for the core catalytic subunit of the polycomb repressive 
complex. Polycombs are highly conserved multimeric proteins that control epigenetic status 
during embryonic development, cell differentiation, and stem cell proliferation, and 
potentially aging [256]. The Ezh2 locus in the BXD family is highly polymorphic and is 
associated with cis-acting variation in expression of the Ezh2 transcript. Work by de Haan 
and colleagues identified Ezh2 as a candidate for hematopoietic stem cell aging, and 
overexpression of this gene rescues stem cell aging [257–259]. On the epigenetics front, 
CpG sites that undergo age-dependent changes in DNA methylation, including the 353 age-
informative sites used to calculate the human epigenetic age, are enriched in genes targeted 
by the polycomb complex [251, 260–262]. This is an example in which the integration of 
genomic and epigenomic data can shed light on some of the mechanistic aspects of an aging 
epigenome. A multi-omic approach and careful integration of epigenomic and genomic 
approaches will be a powerful ally to the genetic cartography of aging and longevity.
Future directions
Progress in unraveling the genetics of longevity is on the threshold of a new phase, poised to 
burst out from the gloom of an infinitesimal model of gene action—thousands of 
polymorphisms with undetectable effects—to the clarity of a large collection of validated 
gene variants. The development of powerful genetics, genomics, and bioinformatics tools is 
enabling a more comprehensive and perhaps even more objective systems analysis of 
longevity networks. By combining discovery-based methods with mechanistic analyses and 
systematic studies of GXE, it is highly likely that over the next decade many new genes, 
networks, and mechanisms will be connected to longevity and aging-related diseases.
We need to make better progress using both huge human cohorts and model organisms, 
including mouse—our most effective mammalian model. Boosting sample sizes is an 
obvious and often effective strategy, but this may not be enough. A better strategy at this 
point is to integrate across species, models, and experiments. Model organisms have already 
proved their worth in longevity research. However, the lack of more intimate collaboration 
between human and model organism researchers remains a barrier. We have some seen some 
strong results from collaboration across species with yeast, mouse, or C. elegans serving as 
instigators and corroborators of key discoveries [31, 122, 167]. Yeast, C. elegans, 
Drosophila, naked mole rats, killifish, and mice can help trace networks and mechanisms of 
longevity, and provide unrivalled access to the next frontier—GXE interactions and aging. 
Our hope is that the next version of this review will not only summarize a much more 
numerous set of longevity gene variants, but showcase new mechanisms that explain how 
genetic, epigenetic, cellular, and hormonal systems interact with environment and lifestyle to 
modify rates of aging. Finally, mechanisms are not enough. We need to aim, and aim rapidly, 
at developing and testing interventions that both increase vigor and reduce diseases and 
functional deficits that accompany aging
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B6 C57BL/6J mouse strain
Chr chromosome
D2 DBA/2J mouse strain
ER endoplasmic reticulum
F1 filial 1 generation
F2 filial 2 generation
GWAS genome-wide association study
GXE gene-by-environmental interaction
HDL high-density lipoprotein
HSR heat shock response
ITP Interventions Testing Program
LOD logarithm of odds
Mb megabase
MHC or H2 major histocompatibility complex
mtDNA mitochondrial DNA
NAD nicotinamide adenine dinucleotide
QTL quantitative trait locus
ROS reactive oxygen species
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UPR unfolded protein response
UPRER unfolded protein response of endoplasmic reticulum
UPRmt unfolded protein response of mitochondria
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Figure 1. 
Illustration of the effect of sample size (x-axis) on the yield of genome-wide association 
study (GWAS) findings (y-axis). Variation in human height (red dots) is a highly complex 
trait with moderate heritability that was refractory to GWAS at sample sizes below ~10,000 
subjects. Longevity studies (stars) were refractory until sample sizes reached ~20,000. 
Longevity points: Deelen et al. (D1) [263], Deelen et al. (D2) [264], Tanaka et al. (T) [265], 
Flachsbart et al. (Fl) [164], Joshi et al. (J) [266], and McDaid et al. (Mc) [31]. Redrawn with 
additions from Visscher et al. [267].
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Figure 2. 
QTLs for mouse longevity adapted from Yuan and colleagues [81] with added peaks from 
Houtkooper et al. [122], Yuan et al. [133], and Newell et al. [152]. We have also added a 
locus on Chr 1 at about 80 Mb detected by remapping data from Rikke et al. [96] via 
GeneNetwork LXS phenotype 10156 (asterisk to right of Chr 1). Length of colored bars 
represents the 95% confidence interval or a 40 Mb interval centered on the peak.
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